New 3PL will add a second facility by year-end; stresses the economies of consolidated shipping
Having opened its doors less than 12 months ago, OM Healthcare Logistics has signed a five-year deal with CareFusion (San Diego), the spinout from Cardinal Health that is also about a year old. OM Healthcare Logistics (OMHL), a business unit of the major medical-device wholesaler Owens & Minor (Richmond, VA), will open a new facility by year-end in Redlands, CA, to handle the new business; combined with the facility in Lexington, KY, the unit will have warehouse capacity of 475,000 sq. ft.
“Becoming the logistics provider for CareFusion is an important step in our efforts to provide the healthcare supply chain with innovative solutions and new logistics efficiencies,” says Craig Smith, president and CEO of O&M. Douglas Witter, VP of sales and marketing at OMHL, says that the company is stressing the economies of consolidated shipping—combining shipments of multiple manufacturers or orders to delivery points. “We can take parcels and make them less-than-truckload (LTL) shipments, and take LTL shipments and make them truckload deliveries,” he says. “The savings in transportation costs can approach 20-40%.”
The OMHL facilities are cGMP-compliant, and the company is registered as a controlled-substances distributor with DEA, as well as a relabeler with FDA. “These capabilities will allow us to perform kitting services in addition to basic warehousing and transportation,” says Witter.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.